Beta Bionics, Inc.BBNXEarnings & Financial Report
Beta Bionics, Inc. is a medical technology company focused on developing and commercializing advanced automated diabetes management solutions. Its core product is the iLet Bionic Pancreas, a wearable device that automatically adjusts insulin and glucagon delivery for people with Type 1 and Type 2 diabetes, serving primarily the U.S. healthcare market with plans for global expansion.
BBNX Q1 FY2026 Key Financial Metrics
Revenue
$27.6M
Gross Profit
$16.4M
Operating Profit
$-13.1M
Net Profit
$-21.9M
Gross Margin
59.5%
Operating Margin
-47.4%
Net Margin
-79.3%
YoY Growth
56.6%
EPS
$-0.49
Beta Bionics, Inc. Q1 FY2026 Financial Summary
Beta Bionics, Inc. reported revenue of $27.6M (up 56.6% YoY) for Q1 FY2026, with a net profit of $-21.9M (up 23.6% YoY) (-79.3% margin). Cost of goods sold was $11.2M, operating expenses totaled $29.5M.
Key Financial Metrics
| Total Revenue | $27.6M |
|---|---|
| Net Profit | $-21.9M |
| Gross Margin | 59.5% |
| Operating Margin | -47.4% |
| Report Period | Q1 FY2026 |
Beta Bionics, Inc. Annual Revenue by Year
Beta Bionics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $100.3M).
Beta Bionics, Inc. Quarterly Revenue & Net Profit History
Beta Bionics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q1 FY2026 | $27.6M | +56.6% | $-21.9M | -79.3% |
| Q4 FY2025 | $32.1M | — | $-13.5M | -41.9% |
| Q3 FY2025 | $27.3M | — | $-14.2M | -52.1% |
| Q2 FY2025 | $23.2M | — | $-16.9M | -72.6% |
| Q1 FY2025 | $17.6M | — | $-28.7M | -162.5% |
Income Statement
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|
| Revenue | $17.6M | $23.2M | $27.3M | $32.1M | $27.6M |
| YoY Growth | N/A | N/A | N/A | N/A | 56.6% |
Balance Sheet
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | |
|---|---|---|---|---|---|
| Assets | $338.0M | $330.0M | $330.0M | $328.7M | $304.4M |
| Liabilities | $24.3M | $28.3M | $35.3M | $41.1M | $33.2M |
| Equity | $313.8M | $301.6M | $294.8M | $287.6M | $271.2M |
Cash Flow
| Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|
| Operating CF | $-20.0M | $-13.6M | $-8.7M | $-8.6M |